Abstracts - PAGE Meeting (Population Approach Group Europe)

← Back to filters

Abstracts (33)

I-18Bojana Golubovic

Population pharmacokinetics of sirolimus in adult kidney transplant patients

Wednesday 10:20-11:50

I-21Mario Gonzalez Sales

Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy volunteers.

Wednesday 10:20-11:50

I-27Chihiro Hasegawa

Modeling & simulation of ONO-5334, a cathepsin K inhibitor, to support dose selection in osteoporosis

Wednesday 10:20-11:50

I-42Niclas Jonsson

A Population PK Analysis of Nebivolol and Valsartan in Combination Therapy

Wednesday 10:20-11:50

I-48Takayuki Katsube

Population PK/PD Modeling of Lusutrombopag, Thrombopoietin Receptor Agonist, in Healthy Volunteers for Exploring PK/PD Covariates

Wednesday 10:20-11:50

I-53Yo Han Kim

Early characterization of ticagrelor using modeling and simulation analysis of the in vitro platelet aggregation test and human pharmacokinetic data

Wednesday 10:20-11:50

I-59Ryuji Kubota

Population Pharmacokinetics of Ospemifene and Evaluation for Exposure Increase

Wednesday 10:20-11:50

II-01Brigitte Lacroix

Modeling the anti-drug antibody response in rheumatoid arthritis patients treated with certolizumab pegol

Wednesday 15:10-16:30

II-07Kha Le

Population PKPD Modeling of Geographic Atrophy Disease Progression, Target Mediated Disposition and Treatment Effect of Lampalizumab

Wednesday 15:10-16:30

II-12Yan Li

PK/PD Modeling of Tumor Growth Inhibition in Xenograft Mice to Optimize Experimental Design and Improve Study Efficiency

Wednesday 15:10-16:30

II-15Jos Lommerse

PKPD model of erythropoietin and hemoglobin response in rats following administration of prolyl hydroxylase inhibitors

Wednesday 15:10-16:30

II-18Mats Magnusson

A Population PK/PD Analysis of Nebivolol and Valsartan Combination Therapy

Wednesday 15:10-16:30

II-23Matilde Merino-Sanjuán

Simulation of Plasmatic Taurine Levels In Well And Undernourished Rats After Enteral Diet Administration.

Wednesday 15:10-16:30

II-25Enrica Mezzalana

A Target-Mediated Drug Disposition model to quantify the relationship between Otelixizumab in vitro concentration and TCR/CD3 engagement

Wednesday 15:10-16:30

II-26Raymond Miller

Modelling and simulation of the activity of intrinsic Factor Xa following edoxaban treatment

Wednesday 15:10-16:30

II-28Dirk Jan Moes

Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in liver transplant patients

Wednesday 15:10-16:30

II-44Sung Min Park

Population pharmacokinetics and CYP3A5 genotype effect of S-amlodipine in healthy Korean male subjects

Wednesday 15:10-16:30

II-47Nathalie Perdaems

Translational PKPD modeling of a cardiovascular drug and the interrelationship between blood pressure and heart rate in animals and human

Wednesday 15:10-16:30

II-49Philippe Pierrillas

Preclinical evaluation of the dose-concentration-marker-tumor growth relationship of a new pro-apoptotic compound using population PK-PD modeling

Wednesday 15:10-16:30

II-58Hyerang Roh

Characterization of Nocturia Patient’s Urination Pattern and Assessment of Drug Treatment Using Joint Ordered Categorical Model

Wednesday 15:10-16:30

III-06Franc Andreu Solduga

Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant patients.

Thursday 10:05-11:30

III-10Ioanna Athanasiadou

Hyperhydration may alter urine pharmacokinetic profile of drugs: A simulation study using budesonide as model drug

Thursday 10:05-11:30

III-14Jan Berkhout

Mechanism-based approaches to the analysis of comparative effectiveness in osteoporosis

Thursday 10:05-11:30

III-23Karl Brendel

Population Pharmacokinetic modelling for a molecule S and its glucuronide metabolite including enterohepatic recycling

Thursday 10:05-11:30

III-30Ana Catalan-Latorre

A Mechanistic Population Pharmacokinetic Model For Taurine In Well And Undernourished Rats

Thursday 10:05-11:30

III-45Emmanuelle Comets

Population pharmacokinetics of mycophenolate acid and its metabolite in liver transplant patients

Thursday 10:05-11:30

III-54Paul Matthias Diderichsen

Dose selection of GLPG0634, a selective JAK1 inhibitor, for rheumatoid arthritis Phase 2B studies: PK/PD modeling of pSTAT1 biomarker and DAS28 clinical response

Thursday 10:05-11:30

IV-04Andre Schäftlein

Population modeling of the relationship between the pharmacokinetics of the oral thrombin inhibitor dabigatran etexilate and coagulation biomarkers in patients with non-valvular atrial fibrillation from the RE-LY trial

Thursday 15:15-16:40

IV-14Mijeong Son

Population Pharmacokinetic-Pharmacodynamic modeling of Olemsartan in Healthy Korean Volunteers

Thursday 15:15-16:40

IV-17Elisabet Størset

Evaluation of dosing strategies to achieve targeted tacrolimus exposure after adult kidney transplantation

Thursday 15:15-16:40

IV-32Pavan Vajjah

Exposure-response relationship of certolizumab pegol in psoriatic arthritis patients and comparison of ACR 20/50/70 response rates in the two dosage regimens

Thursday 15:15-16:40

IV-45Franziska Weber

Evaluation of candidate drugs to induce the redundant gene ABCD2 as an alternative treatment option for X-linked adrenoleukodystrophy

Thursday 15:15-16:40

IV-48Pawel Wiczling

PK/PD of propofol and fentanyl in patients undergoing abdominal aortic surgery – the influence of cardiac output and drug interactions

Thursday 15:15-16:40